Future Pregnancies and Recurrence Prior guidelines have summarized the studies examining the outcome and complication rates of pregnancy in women who These studies found that the risk of complications during future pregnancies was low. There was a high propor- tion of spontaneous abortion, consistent with emerging obser- On the basis of the available evidence, CVT is not a contraindication for future pregnancies; however, many of the patients followed up for recurrences were main- tained on preventive antithrombotic medication. Considering the additional risk that pregnancy confers to women with a history of CVT, prophylaxis with LMWH during future preg- nancies and the postpartum period may be beneficial.200 CVT: Summary and Gaps There is a striking sex difference in CVT incidence that is related to hormonal factors and pregnancy. Long-term oral anticoagulation is recommended for patients at high risk of recurrence because of thrombophilia, but overall recurrence rates are low, even with subsequent pregnancy. Long-term data on sex differences in recurrence and on functional out- comes are lacking. CVT: Recommendations 1. In patients with suspected CVT, routine blood stud- ies consisting of a complete blood count, chemis- try panel, prothrombin time, and activated partial thromboplastin time should be performed (Class I; Level of Evidence C). 2. Screening for potential prothrombotic conditions that may predispose a person to CVT (eg, use of con- traceptives, underlying inflammatory disease, infec- tious process) is recommended in the initial clinical assessment (Class I; Level of Evidence C). 3. Testing for prothrombotic conditions, including protein C, protein S, or antithrombin deficiency; antiphospholipid syndrome; prothrombin G20210A mutation; and factor V Leiden can be beneficial for the management of patients with CVT. Testing for protein C, protein S, and antithrombin deficiency is generally indicated 2 to 4 weeks after completion of anticoagulation. 